down arrow

Carna Biosciences, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3220550002
JPY
384.00
160 (71.43%)

Dec 11

TKS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
GNI Group Ltd.
OncoTherapy Science, Inc.
Cyfuse Biomedical KK
MEDINET Co., Ltd.
SUSMED, Inc.
Stella Pharma Corp.
Oncolys BioPharma, Inc.
Chiome Bioscience, Inc.
StemCell Institute
Peptidream, Inc.
Carna Biosciences, Inc.
Why is Carna Biosciences, Inc. ?
1
Poor Management Efficiency with a low ROE of 0%
  • The company has reported losses. Due to this company has reported negative ROE
2
Poor long term growth as Operating profit has grown by an annual rate -215.58% of over the last 5 years
3
With a fall in Net Profit of -2.23%, the company declared Very Negative results in Jun 25
  • The company has declared negative results for the last 4 consecutive quarters
  • The company has declared negative results in Jun 24 after 2 consecutive negative quarters
  • NET PROFIT(9M) At JPY -1,558.03 MM has Grown at -53.89%
  • ROCE(HY) Lowest at -92.94%
  • RAW MATERIAL COST(Y) Grown by 6.5% (YoY)
4
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 23.08%, its profits have fallen by -113.3%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Carna Biosciences, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Carna Biosciences, Inc.
23.08%
28.28
67.92%
Japan Nikkei 225
28.54%
1.11
25.75%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
-29.23%
EBIT Growth (5y)
-215.58%
EBIT to Interest (avg)
-358.28
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.77
Sales to Capital Employed (avg)
0.35
Tax Ratio
0.13%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.14
EV to EBIT
-2.15
EV to EBITDA
-2.17
EV to Capital Employed
10.28
EV to Sales
7.73
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-479.32%
ROE (Latest)
-111.86%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company
NET PROFIT(HY)

Higher at JPY -1,055.74 MM

-22What is not working for the Company
NET PROFIT(9M)

At JPY -1,558.03 MM has Grown at -53.89%

ROCE(HY)

Lowest at -92.94%

RAW MATERIAL COST(Y)

Grown by 6.5% (YoY

CASH AND EQV(HY)

Lowest at JPY 2,589.91 MM

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.06%

NET SALES(Q)

Lowest at JPY 107.75 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -515.59 %

Here's what is working for Carna Biosciences, Inc.
Net Profit
Higher at JPY -1,055.74 MM
than preceding 12 month period ended Jun 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (JPY MM)

Here's what is not working for Carna Biosciences, Inc.
Net Sales
At JPY 107.75 MM has Fallen at -28.01%
over average net sales of the previous four periods of JPY 149.68 MM
MOJO Watch
Near term sales trend is extremely negative

Net Sales (JPY MM)

Net Sales
Lowest at JPY 107.75 MM
in the last five periods
MOJO Watch
Near term sales trend is negative

Net Sales (JPY MM)

Operating Profit Margin
Lowest at -515.59 %
in the last five periods
MOJO Watch
Company's profit margin has deteriorated

Operating Profit to Sales

Cash and Eqv
Lowest at JPY 2,589.91 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Inventory Turnover Ratio
Lowest at 1.06%
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Raw Material Cost
Grown by 6.5% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."